Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + GM-CSF in CLL
NCT00940342Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2004
- Primary completion
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim in chronic lymphocytic leukemia (CLL), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2004; status: completed.
02
Drugs
sargramostim
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00940342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00940342.